Literature DB >> 9101084

Protein kinase C-beta 2 inhibits cycling and decreases c-myc-induced apoptosis in small cell lung cancer cells.

L F Barr1, S E Campbell, S B Baylin.   

Abstract

The overexpression of c-myc frequently accompanies the relapse of small cell lung cancer (SCLC) cells and contributes to the poor prognosis of this tumor. In this study, we confirm that transfected c-myc results in decreased homotypic cell aggregation and increased proliferative capacity of SCLC cells when nutrient conditions are adequate. We also find that c-myc contributes to apoptosis when cells are nutrient depleted, and flow cytometry suggests that this enhanced apoptosis is associated with a failure to halt cell cycling, consistent with the experience in other cell types. We previously found that protein kinase C-beta (PKC-beta) expression in NCI H209 (209) SCLC cells increases markedly with c-myc transfection (L. F. Barr et al., Cancer Res., 51: 5514-5519, 1991), and we hypothesized that PKC-beta may mediate some of the effects of c-myc in these cells. We test this hypothesis by transfection of rat PKC-beta 1 and bovine PKC-beta 2 isoforms into 209 cells before and after transfection with c-myc. PKC-beta 1 transfection has no effect on these cells. However, PKC-beta 2 expression has distinct phenotypic consequences. In the parental cells, PKC-beta 2 expression results in increased homotypic cell aggregation and a prolonged doubling time. Furthermore, PKC-beta 2 expression increases the fraction of these cells in G0-G1. In the cells which express a transfected c-myc gene, PKC-beta 2 expression improves the survival of cells in low serum by decreasing myc-induced apoptosis. This effect was associated with, and may be mediated by, a selection for cells in the G0-G1 fraction. We postulate that transfection of c-myc into SCLC cells may select for those expressing the PKC-beta 2 gene because this signal transduction event protects against myc-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101084

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

Review 1.  Molecular biology of protein kinase C signaling in cardiac myocytes.

Authors:  A Malhotra; B P Kang; D Opawumi; W Belizaire; L G Meggs
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

2.  Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.

Authors:  Sang-Haak Lee; Tingan Chen; Jun Zhou; Jennifer Hofmann; Gerold Bepler
Journal:  Clin Lung Cancer       Date:  2010-05       Impact factor: 4.785

3.  Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells.

Authors:  Amandine Hurbin; Jean-Luc Coll; Laurence Dubrez-Daloz; Bernard Mari; Patrick Auberger; Christian Brambilla; Marie-Christine Favrot
Journal:  J Biol Chem       Date:  2005-03-14       Impact factor: 5.157

4.  Glycochenodeoxycholic acid (GCDC) induced hepatocyte apoptosis is associated with early modulation of intracellular PKC activity.

Authors:  B Gonzalez; C Fisher; B G Rosser
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

5.  A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.

Authors:  Sukhmani K Padda; Yelena Krupitskaya; Laveena Chhatwani; George A Fisher; Alexander D Colevas; Melanie San Pedro-Salcedo; Rodney Decker; Jane E Latz; Heather A Wakelee
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-11       Impact factor: 3.333

6.  Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

Authors:  T Shimokawa; M Seike; C Soeno; H Uesaka; A Miyanaga; H Mizutani; K Kitamura; Y Minegishi; R Noro; T Okano; A Yoshimura; A Gemma
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

7.  Calcium signalling links MYC to NUAK1.

Authors:  T Monteverde; J Tait-Mulder; A Hedley; J R Knight; O J Sansom; D J Murphy
Journal:  Oncogene       Date:  2017-11-06       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.